Resverlogix Corp   Report issue

For profit Phase 3
Founded: Calgary AB Canada (2000)

Organization Overview

First Clinical Trial
2008
NCT00768274
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Resverlogix Corp